Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV002210999 | SCV002496316 | uncertain significance | not provided | 2022-02-17 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation as the last 87 amino acids are replaced with 66 different amino acids, although loss-of-function is not a known mechanism of disease; Has not been previously published as pathogenic or benign to our knowledge |
Mayo Clinic Laboratories, |
RCV002210999 | SCV004224385 | uncertain significance | not provided | 2023-02-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002210999 | SCV004521648 | uncertain significance | not provided | 2023-08-04 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 1675270). This variant has not been reported in the literature in individuals affected with GFAP-related conditions. This variant is present in population databases (rs765762750, gnomAD 0.007%). This sequence change creates a premature translational stop signal (p.Leu346Glnfs*67) in the GFAP gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 87 amino acid(s) of the GFAP protein. |